MedPath

Ohsu Knight Cancer Institute

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.ohsu.edu/knight-cancer-institute

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

Phase 2
Active, not recruiting
Conditions
Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8
Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Liver and Intrahepatic Bile Duct Carcinoma
Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Device: Implanted Medical Device
Other: Quality-of-Life Assessment
First Posted Date
2020-02-05
Last Posted Date
2025-04-18
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
5
Registration Number
NCT04251715
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Progressive Resistance Training for the Improvement of Physical Function

Not Applicable
Completed
Conditions
Sarcoma
Interventions
Other: Exercise Counseling
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Other: Resistance Training
First Posted Date
2020-01-30
Last Posted Date
2022-08-08
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
10
Registration Number
NCT04247425
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Hyperspectral Endoscopy Imaging for the Early Detection of Precancerous Lesions in Average Risk Patients

Not Applicable
Completed
Conditions
Patient
Interventions
Procedure: Hyperspectral Endoscopy (HySE)
Device: White Light Endoscopy (WLE)
First Posted Date
2019-11-21
Last Posted Date
2020-05-08
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
13
Registration Number
NCT04172493
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Whole Body Vibration for the Improvement of Health and Functioning in Participants With Chemotherapy-Induced Peripheral Neuropathy

Not Applicable
Completed
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Chemotherapy-Induced Peripheral Neuropathy
Interventions
Behavioral: Whole Body Vibration
First Posted Date
2019-11-20
Last Posted Date
2023-08-30
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
38
Registration Number
NCT04170075
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

Phase 1
Active, not recruiting
Conditions
Rectal Adenocarcinoma
Stage IIA Rectal Cancer AJCC v8
Stage III Rectal Cancer AJCC v8
Stage IIIA Rectal Cancer AJCC v8
Stage IIIB Rectal Cancer AJCC v8
Stage IIB Rectal Cancer AJCC v8
Stage IIIC Rectal Cancer AJCC v8
Interventions
Radiation: 3-Dimensional Conformal Radiation Therapy
Radiation: Intensity-Modulated Radiation Therapy
First Posted Date
2019-09-26
Last Posted Date
2025-02-14
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
18
Registration Number
NCT04104139
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Early Phase 1
Recruiting
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma
Stage II Pancreatic Cancer AJCC v8
Stage IV Pancreatic Cancer AJCC v8
Metastatic Pancreatic Ductal Adenocarcinoma
Stage III Pancreatic Cancer AJCC v8
Unresectable Pancreatic Ductal Adenocarcinoma
Borderline Resectable Pancreatic Ductal Adenocarcinoma
Resectable Pancreatic Ductal Adenocarcinoma
Interventions
First Posted Date
2019-07-02
Last Posted Date
2025-02-13
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
90
Registration Number
NCT04005690
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer

Phase 2
Terminated
Conditions
Stage IA1 Lung Cancer AJCC v8
Stage II Lung Cancer AJCC v8
Stage IIB Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8
Extensive Stage Lung Small Cell Carcinoma
Stage IIIA Lung Cancer AJCC v8
Limited Stage Lung Small Cell Carcinoma
Stage I Lung Cancer AJCC v8
Stage IA2 Lung Cancer AJCC v8
Stage IA3 Lung Cancer AJCC v8
Interventions
Other: Questionnaire Administration
Device: Tumor Treating Fields Therapy
First Posted Date
2019-06-24
Last Posted Date
2023-10-30
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
3
Registration Number
NCT03995667
Locations
🇺🇸

Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States

🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Glucarpidase After High-Dose Methotrexate in Patients with Osteosarcoma

Early Phase 1
Active, not recruiting
Conditions
Osteosarcoma
Interventions
Other: Quality-of-Life Assessment
First Posted Date
2019-05-22
Last Posted Date
2025-01-10
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
12
Registration Number
NCT03960177
Locations
🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1
Terminated
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma
Interventions
First Posted Date
2019-03-18
Last Posted Date
2024-03-04
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
2
Registration Number
NCT03878524
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

Not Applicable
Terminated
Conditions
Hepatocellular Carcinoma
Interventions
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Stereotactic Body Radiation Therapy
First Posted Date
2019-01-23
Last Posted Date
2025-03-07
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
9
Registration Number
NCT03812289
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

© Copyright 2025. All Rights Reserved by MedPath